Nina Xue

1.2k total citations
46 papers, 896 citations indexed

About

Nina Xue is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Nina Xue has authored 46 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 10 papers in Oncology and 9 papers in Immunology. Recurrent topics in Nina Xue's work include Sphingolipid Metabolism and Signaling (6 papers), Epigenetics and DNA Methylation (5 papers) and Heat shock proteins research (5 papers). Nina Xue is often cited by papers focused on Sphingolipid Metabolism and Signaling (6 papers), Epigenetics and DNA Methylation (5 papers) and Heat shock proteins research (5 papers). Nina Xue collaborates with scholars based in China, Czechia and Macao. Nina Xue's co-authors include Xiaoguang Chen, Ming Ji, Fangfang Lai, Jing Jin, Ju Chen, Xiaoguang Chen, Ming Ji, Wenbin Li, Qin Zhou and Tingting Du and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Analytical Biochemistry.

In The Last Decade

Nina Xue

44 papers receiving 883 citations

Peers

Nina Xue

IMMUN

ONCOL

Yung-Luen Shih Taiwan

Mohammad Jalili‐Nik Iran

Xu Zheng China

Xiaoling Luo China

Anqi Zeng China

Yuxin Li China

Wan‐Jung Lu Taiwan

Chaomei Liu United States

Jian Zuo China

Yung-Luen Shih Taiwan

Nina Xue

547 ×1.1

71 ×0.5

IMMUN

111 ×0.8

ONCOL

111 ×1.2

68 ×0.8

Citations per year, relative to Nina Xue Nina Xue (= 1×) peers Yung-Luen Shih

Countries citing papers authored by Nina Xue

Since Specialization

Citations

This map shows the geographic impact of Nina Xue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nina Xue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nina Xue more than expected).

Fields of papers citing papers by Nina Xue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nina Xue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nina Xue. The network helps show where Nina Xue may publish in the future.

Co-authorship network of co-authors of Nina Xue

This figure shows the co-authorship network connecting the top 25 collaborators of Nina Xue. A scholar is included among the top collaborators of Nina Xue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nina Xue. Nina Xue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Mingjin, Zhenyan Hou, Weida Wang, et al.. (2024). ACAT1 Induces the Differentiation of Glioblastoma Cells by Rewiring Choline Metabolism. International Journal of Biological Sciences. 20(14). 5576–5593. 1 indexed citations

Du, Tingting, Xiaowen Hu, Zhenyan Hou, et al.. (2024). Re-expression of epigenetically silenced PTPRR by histone acetylation sensitizes RAS-mutant lung adenocarcinoma to SHP2 inhibition. Cellular and Molecular Life Sciences. 81(1). 64–64.

Wang, Weida, Mingjin Wang, Tingting Du, et al.. (2023). SHMT2 Promotes Gastric Cancer Development through Regulation of HIF1α/VEGF/STAT3 Signaling. International Journal of Molecular Sciences. 24(8). 7150–7150. 18 indexed citations

Wang, Mingjin, Zhenyan Hou, Weida Wang, et al.. (2023). Chlorogenic Acid Induced Neuroblastoma Cells Differentiation via the ACAT1-TPK1-PDH Pathway. Pharmaceuticals. 16(6). 877–877. 8 indexed citations

Hou, Zhenyan, Songwen Lin, Tingting Du, et al.. (2023). S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals. 16(5). 749–749. 2 indexed citations

Mei, Mei, Linfeng Tang, Hao Zhou, Nina Xue, & Ming Li. (2023). Honokiol prevents lung metastasis of triple-negative breast cancer by regulating polarization and recruitment of macrophages. European Journal of Pharmacology. 959. 176076–176076. 7 indexed citations

Wang, Mingjin, Weida Wang, Zhenyan Hou, et al.. (2023). ACAT1 deficiency in myeloid cells promotes glioblastoma progression by enhancing the accumulation of myeloid-derived suppressor cells. Acta Pharmaceutica Sinica B. 13(12). 4733–4747. 12 indexed citations

Fu, Rong, Jun Tai, Xia Yuan, et al.. (2022). S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung. Acta Pharmaceutica Sinica B. 13(3). 1110–1127. 7 indexed citations

Du, Tingting, Songwen Lin, Ming Ji, et al.. (2020). A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity. Cancer Letters. 495. 22–32. 18 indexed citations

10.

Kang, Zhuang, Junting Zhang, Nina Xue, et al.. (2019). KLF7 promotes polyamine biosynthesis and glioma development through transcriptionally activating ASL. Biochemical and Biophysical Research Communications. 514(1). 51–57. 32 indexed citations

11.

Jin, Jing, Ming Ji, Rong Fu, et al.. (2019). Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis. Frontiers in Pharmacology. 10. 1085–1085. 13 indexed citations

12.

Yu-bin, JI, Yichen Liu, Nina Xue, et al.. (2019). <p>Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation</p>. OncoTargets and Therapy. Volume 12. 883–896. 20 indexed citations

13.

Jin, Jing, Nina Xue, Yuan Liu, et al.. (2019). A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharmaceutica Sinica B. 10(2). 276–288. 28 indexed citations

14.

Huang, Shuai, Lulu Wang, Nina Xue, et al.. (2019). Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation. Theranostics. 9(23). 6745–6763. 139 indexed citations

15.

Ji, Ming, Nina Xue, Fangfang Lai, et al.. (2018). The Development of a Biotinylated NAD+-Applied Human Poly(ADP-Ribose) Polymerase 3 (PARP3) Enzymatic Assay. SLAS DISCOVERY. 23(6). 545–553. 6 indexed citations

16.

Xue, Nina, Qin Zhou, Ming Ji, et al.. (2017). Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Scientific Reports. 7(1). 39011–39011. 144 indexed citations

17.

Chen, Wei, Hongying Liu, Hua Guan, Nina Xue, & Lili Wang. (2017). Cannabinoid CB1 receptor inverse agonist MJ08 stimulates glucose production via hepatic sympathetic innervation in rats. European Journal of Pharmacology. 814. 232–239. 3 indexed citations

18.

Zhang, Sen, Dongjie Wang, Nina Xue, et al.. (2017). Nicousamide protects kidney podocyte by inhibiting the TGFβ receptor II phosphorylation and AGE-RAGE signaling.. PubMed Central. 9(1). 115–125. 12 indexed citations

19.

Zhou, Qin, Ming Ji, Jie Zhou, et al.. (2016). Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. Biochemical Pharmacology. 107. 29–40. 15 indexed citations

20.

Zhu, Zhixiang, Jing Jin, Nina Xue, Xiu‐Yun Song, & Xiaoguang Chen. (2014). Development and validation of high-throughput screening assays for poly(ADP-ribose) polymerase-2 inhibitors. Analytical Biochemistry. 449. 188–194. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact